EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in…
TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, is happy to announce the…
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…
The customised study, commissioned by Fairfest Media and conducted by NielsenIQ, the leader in consumer intelligence, indicated that travel industry…
CU Empowers Students with Global Exposure from Harvard to Walt Disney World CHANDIGARH, India, June 2, 2025 /PRNewswire/ -- Chandigarh:…
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials SINGAPORE, June…